Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today presented new preclinical data demonstrating the ability of its Toll-like receptor (TLR) antagonist, IMO-8400, to inhibit the survival and proliferation of B-cell lymphoma cells harboring the oncogenic MYD88 L265P genetic mutation. These data add to the growing body of research which supports the Company’s efforts to develop IMO-8400 for the treatment of genetically defined forms of B-cell lymphoma. The findings were presented today in a poster session titled “Immune Modulatory Agents and Interventions” at the 2014 American Association for Cancer Research (AACR) Annual Meeting in San Diego, California.
Help employers find you! Check out all the jobs and post your resume.
